In The News

BioPharm InsightCites Ropes & Gray as Top Legal Advisor by Global Value in 2014

Practices: Life Sciences

BioPharm Insight, a leading life sciences-focused news service and market analytics guide, ranked Ropes & Gray as the top legal advisor for licensing transactions globally by value in 2014.

Ropes & Gray led the global value table and the North American value table with 19 licensing transactions in 2014 valued at $5.9 billion. The firm’s performance was bolstered by a strong fourth quarter, with Ropes & Gray advising on six deals valued at $4 billion. The firm’s work in 2014 included:

  • Advising Pfizer concerning a collaborative agreement with Germany's Merck KGaA to develop and market an anti-PD-L1 antibody designed to treat various types of tumors. Pursuant to the agreement, Merck will receive $850 million for the opportunity to develop the drug with Pfizer, and could receive an additional $2 billion in milestone payments, dependent on regulatory review and commercial performance. This matter represents the largest deal in the pharmaceuticals industry for a single asset in Phase 2 development.

“We are grateful for the trust and confidence that our clients place in our team with their most important strategic transactions,” said Ropes & Gray partner Marc Rubenstein, co-chair of the firm’s global life sciences practice. “The value and volume of licensing deals that Ropes & Gray handled last year reflect that level of trust and confidence.”

Companies around the world turn to Ropes & Gray’s global life sciences practice for internationally recognized counsel on virtually all matters impacting biotechnology, pharmaceutical and medical device businesses. For more information on our life sciences capabilities, click here.

Cookie Settings